CPDE18712-BENEFIT Trial - New Asian data

Medcomet

This module highlights data from the BENEFIT-KOREA trial, a trial which assess the efficacy and safety of nebivolol in Asian hypertensive patients. Additionally, Professor Manolis also shares insights on key recommendations on the management of hypertension from the ESC/ESH guidelines, as well as the benefits of nebivolol in comparison to other β-blockers.

This Continuous Medical Education (CME) is supported by Menarini Singapore Ptd Ltd.

You must be a member to access this content.

To become a member, please register here.

If you're already a member, please sign in to access.